ArticleALTEX2022
U.S. Federal Agency interests and key considerations for new approach methodologies for nanomaterials.
Article in ALTEX, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Evaluation of sources of variability in a nitric oxide screening assay for engineered nanomaterials.Nanomedicine : nanotechnology, biology, and medicine · 2026Article
- Cardiovascular Toxicity of Metal-Based Nanoparticles.International journal of molecular sciences · 2025Review
- Derivation of Particle Number Concentration from the Size Distribution: Theory and Applications.Analytical chemistry · 2025Article
- Article
- Protocols for isolation and characterization of nanoparticle biomolecular corona complexes.Frontiers in toxicology · 2024Article
- Cheminformatics and Machine Learning Approaches to Assess Aquatic Toxicity Profiles of Fullerene Derivatives.International journal of molecular sciences · 2023Article
- U. S. federal perspective on critical research issues in nanoEHS.Environmental science. Nano · 2023Article
- Risk Assessment of Nanomaterials Toxicity.Nanomaterials (Basel, Switzerland) · 2023Article
- Technical framework for enabling high quality measurements in new approach methodologies (NAMs).ALTEX · 2023Article
- Potential Artifacts and Control Experiments in Toxicity Tests of Nanoplastic and Microplastic Particles.Environmental science & technology · 2022Review
- Current ecotoxicity testing needs among selected U.S. federal agencies.Regulatory toxicology and pharmacology : RTP · 2022Review
- IVIVE: Facilitating the Use ofToxics · 2022Review
- Neurotoxicity of Engineered Nanomaterials: Testing Considerations.Frontiers in public health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Engineered nanomaterials (ENMs) come in a wide array of shapes, sizes, surface coatings, and compositions, and often possess novel or enhanced properties compared to larger sized particles of the same elemental composition. To ensure the safe commercialization of products containing ENMs, it is important to thoroughly understand their potential risks. Given that ENMs can be created in an almost infinite number of variations, it is not feasible to conduct in vivo testing on each type of ENM. Instead, new approach methodologies (NAMs) such as in vitro or in chemico test methods may be needed, given their capacity for higher throughput testing, lower cost, and ability to provide information on toxicological mechanisms. However, the different behaviors of ENMs compared to dissolved chemicals may challenge safety testing of ENMs using NAMs. In this study, member agencies within the Interagency Coordinating Committee on the Validation of Alternative Methods were queried about what types of ENMs are of agency interest and whether there is agency-specific guidance for ENM toxicity testing. To support the ability of NAMs to provide robust results in ENM testing, two key issues in the usage of NAMs, namely dosimetry and interference/bias controls, are thoroughly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.